Prevention of Gram-Negative Shock and Death in Surgical Patients by Antibody to Endotoxin Core Glycolipid

Antibiotic Therapy, Endotoxin Concentration in Cerebrospinal Fluid, and Brain Edema in Experimental Escherichia coli Meningitis in Rabbits

“…Antibodies to the glycolipid core region of endotoxin have attracted major attention as tools in the prevention or treatment of the septic complications associated with gram-negative bacteremia [36,37]. Because the core region of lipopolysaccarides of different gram-negative bacteria is relatively stable immunologically, antibodies to the core region of one strain are protective against the endotoxin of different strains [38,39].…”

Use of Immunoglobulins in Prevention and Treatment of Infection in Critically III Patients: Review and Critique

“…As already noted, in both successful clinical studies with E. coli J5 antiserum [36,37], the protection remained of unclear origin because outcome could not be convincingly correlated with the level of antibodies to the core LPS of E. coli J5 ( [36] and D. Heumann and J-D Baumgartner, unpublished data). In addition, it was found that in 70 volunteers who donated their plasma for one of these studies [37], immunization with E. coli J5 vaccine(providedby E. 1.…”

“…In a randomized, double-blind, prophylactic trial, Baumgartner and colleagues [37] were able to show that plasma from volunteers immunized with E. coli 15 protected surgical patients who were at high risk for gram-negative infection from shock and death. On admission to the intensive care unit, patients receivedplasma harvested from donors who had been immunized againstE.…”

“…In addition, it was found that in 70 volunteers who donated their plasma for one of these studies [37], immunization with E. coli J5 vaccine(providedby E. 1. Ziegler) induced a modest threefold increase in antibodies to the LPS of E. coli J5 but no increase in antibodies to Re LPS or to lipid A [39].…”

A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595 lipopolysaccharide

“…Therefore, great emphasis has been placed on characterising antisera raised against strains deficient in the 0-antigens (rough, R, mutants), in particular the Rmutants of Escherichia coli 0 1 11 : B4 (E. coli J5) and Salmonella minnesota (S. minnesota R595), which express only lipid A and a portion of the core oligosaccharide as their LPS (reviewed by Zinner and Peter, 1983). Experimental work in animals (Ziegler et al, 1973 ;Braude et al, 1977) and clinical studies (Ziegler et al, 1982;Baumgartner et al, 1985) have shown the protective efficacy of such antisera. However, not all investigators have found consistent protection (Ng et al, 1976;Greisman et al, 1978;Van Dijk et al, 1981).…”